VOXCAN is a private CRO type company, created in 2007, which offers innovative preclinical services through medical imaging, making it possible to improve and accelerate the development of new therapies, in an ethical and economic manner (reduction up to to 80% of the number of animals used), and reduce time to market.

Infectiology, oncology and osteoarticular pathologies are the main areas of expertise in which Voxcan has strong experience.

We carry out all our studies in our new preclinical platform (animal facility and imagery) of 500m2, located near Lyon (France), with bio-containment areas (BSL2 & BSL3).

In infectious diseases, we can offer in-vivo efficacy studies of your drug candidates in many models of bacterial infection (osteoarticular infection, biofilm on intravenous, pulmonary, subcutaneous catheter on medical tissue, etc.), but also viral or fungal, requiring bio-containment type 2 (BSL-2). We can also use bioluminescent infectious strains (bacterial or viral) allowing, via optical imaging, real-time monitoring of the infection. Voxcan also has its own type 3 bio-containment zone (BSL-3) for infectious challenges requiring a high level of containment.

In oncology, we provide you with preclinical services ranging from the in-vitro determination of the action mechanism of the treatment (chemotherapies, antibodies, ADC, immunotherapies…) to in-vivo studies using subcutaneous (ectopic) or orthotopic murine tumor models (Colorectal, Glioblastoma, Pulmonary, Pancreatic, Gastric, Ovarian, Leukemia, Lymphoma, Myeloma… Cancer models).